Elderly patients with acute myeloid leukemia (AML) or patients with relapsed/refractory (R/R) AML have poor outcomes and require new therapeutic options. Venetoclax with hypomethylating agents is now an approved combination for newly diagnosed AML in older or intensive chemotherapy-ineligible patients. Here, Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, updates us on two ongoing studies: a phase 2 trial of venetoclax with 10-day decitabine (NCT03404193) and the combination on venetoclax with cladribine/low dose AraC in older or unfit patients in the newly diagnosed setting. She also discusses the real world data for venetoclax in combination with antifungals agent. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.